Cargando…

A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea

Detalles Bibliográficos
Autores principales:	Song, Ilgeun, Lee, Dong-hyun, Lee, Je-Hwan, Jang, Seongsoo, Huh, Joo-Ryung, Seo, Eul-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Laboratory Medicine 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697351/ https://www.ncbi.nlm.nih.gov/pubmed/26522767 http://dx.doi.org/10.3343/alm.2016.36.1.79

Ejemplares similares

t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5
por: Ehrentraut, Stefan, et al.
Publicado: (2013)

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
por: Sun, Yingxin, et al.
Publicado: (2021)

PCM 89-05
Publicado: (1989)

PCM 89-03
Publicado: (1989)

PCM 89-04
Publicado: (1989)

PCM 89-1
Publicado: (1989)

PCM 89 - 06
por: Kuiper, B
Publicado: (1989)

Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)
por: Chamseddine, A. N., et al.
Publicado: (2015)

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2(V617F) Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review
por: Zhang, Lina, et al.
Publicado: (2023)

PCM1-JAK2 Fusion in a Patient With Acute Myeloid Leukemia
por: Lee, Jong-Mi, et al.
Publicado: (2018)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm
por: Park, Sang Hyuk, et al.
Publicado: (2013)

JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation
por: Sassi, Hela, et al.
Publicado: (2021)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease
por: Elnaggar, Mohamed M, et al.
Publicado: (2012)

Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms
por: Kim, Jae-Ryuk, et al.
Publicado: (2016)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
por: Zaroogian, Zachary, et al.
Publicado: (2023)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
por: Zhao, Ailin, et al.
Publicado: (2023)

Antibacterial activity identification of pCM19 and pCM12 derived from hGlyrichin
por: Sha, Jibin, et al.
Publicado: (2016)

The First Case Report of JAK2–BCR–PPP1R32 Fusion Genes Because of a Translocation (9;22;11)(p24;q11.2;q13) in a Patient With Myeloproliferative Neoplasm
por: Xie, Huan, et al.
Publicado: (2023)

Extramedullary T-lymphoblastic Crisis in a Myelodysplastic/Myeloproliferative Neoplasm with a t(12;22)/MN1::ETV6 Translocation
por: Freitas, Ana Carolina, et al.
Publicado: (2023)

Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation
por: Kim, Bohyun, et al.
Publicado: (2020)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
por: Bellido, Mar, et al.
Publicado: (2012)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nlei7nqms3mef1kns7tocmj0ir